NEW YORK, August 24, 2017 /PRNewswire/ --
If you want a Stock Review on DXTR, XRAY, BAX, or MZOR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com revisits the Medical Instruments and Supplies industry, which primarily researches, develops, and produces non-electronic medical, surgical, dental, and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, blood transfusion equipment, and catheters. Under review this morning are: Dextera Surgical Inc. (NASDAQ: DXTR), DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Baxter International Inc. (NYSE: BAX), and Mazor Robotics Ltd (NASDAQ: MZOR). Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
Shares in California-based Dextera Surgical Inc. jumped 7.75%, ending Wednesday's trading session at $0.34. The stock recorded a trading volume of 21.18 million shares, which was higher than its three months average volume of 6.92 million shares. The Company's shares have surged 40.73% in the last one month and 82.43% over the last three months. The stock is trading 28.52% above its 50-day moving average. Moreover, shares of Dextera Surgical, which designs and manufactures proprietary stapling devices for minimally invasive surgical procedures in the US, Japan, Germany, and internationally, have a Relative Strength Index (RSI) of 68.31.
On August 16th, 2017, research firm Ladenburg Thalmann initiated a 'Buy' rating on the Company's stock, with a target price of $0.80 per share.
On August 21st, 2017, Dextera Surgical announced that Julian Nikolchev, President and CEO, will present a corporate update at the Southern California Investor Conference on August 24th, 2017, at 8:30 a.m. PT in Newport Beach, CA. The live and subsequently archived webcast of the presentation may be accessed under the Investor Relations section of the Company's website. Visit us today and access your complete report on DXTR for free at:
Pennsylvania headquartered DENTSPLY SIRONA Inc.'s stock declined 0.88%, closing the day at $53.22 with a total trading volume of 1.20 million shares. The Company's shares are trading 12.91% below their 200-day moving average. Shares of the Company, which designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide, have an RSI of 21.36.
On August 09th, 2017, DENTSPLY SIRONA announced its financial results for the three months ended June 30th, 2017. For Q2 2017, net sales were $992.7 million; net loss was $1,050.0 million, or a loss of $4.58 per share; and adjusted net earnings per diluted share were $0.65. Management is also updating its adjusted EPS guidance for 2017 to the range of $2.65 to $2.75 per diluted share.
On August 14th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $74 a share to $68 a share. The complimentary research report on XRAY can be accessed at:
On Wednesday, shares in Illinois headquartered Baxter International Inc. recorded a trading volume of 1.82 million shares. The stock ended the day 1.13% lower at $61.45. The Company's shares have advanced 5.33% in the previous three months and 38.59% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.39% and 16.05%, respectively. Furthermore, shares of Baxter, which provides a portfolio of renal and hospital products, have an RSI of 55.27.
On August 17th, 2017, research firm Citigroup initiated a 'Neutral' rating on the Company's stock, with a target price of $63 per share.
On August 21st, 2017, Baxter announced that it will present at the Morgan Stanley 15th Annual Global Healthcare Conference on September 11th, 2017, in New York. José E. Almeida, Chairman and CEO, is scheduled to present at 1:40 p.m. ET. The live webcast of the Company's presentation can be accessed, and will be available for replay through November 11th, 2017. Register for free on DailyStockTracker.com and download the research report on BAX at:
Israel-based Mazor Robotics Ltd's stock dropped 1.07%, finishing yesterday's session at $38.07 with a total trading volume of 114,562 shares. The Company's shares have surged 73.68% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.84% and 27.56%, respectively. Additionally, shares of Mazor Robotics, which together with its subsidiary, Mazor Robotics Inc., is engaged in the development, production, marketing, and servicing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the US, Western Europe, Eastern Europe, and Asia, have an RSI of 53.07.
On August 01st, 2017, Mazor Robotics reported Q2 2017 results. Revenue for the three months ended June 30th, 2017, was a record $15.5 million; gross margin was 69.4%; and cash used in operating activities was $7.4 million. As of June 30th, 2017, cash, cash equivalents, and investments totaled $57.4 million. Get free access to your research report on MZOR at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207) 331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.